Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278375 | 0.86 | GAA (0.46) | GAAL3MBTL1BCHE | |
| SCHEMBL29706727 | 0.84 | GAA (0.47) | GAAL3MBTL1TAAR1BCHE | |
| SCHEMBL20842979 | 0.82 | CTSS (0.45) | GAAL3MBTL1CYP3A4HPGDCYP2C19 | |
| SCHEMBL16191094 | 0.81 | RIPK1 (0.50) | GAAL3MBTL1CYP3A4HPGDCYP2C19 | |
| SCHEMBL29706730 | 0.81 | SLC6A2 (0.54) | GAAHPGDRAB9A | |
| SCHEMBL8326386 | 0.81 | GBA1 (0.50) | TAAR1 | |
| SCHEMBL7473420 | 0.81 | TAAR1 (0.45) | GAAL3MBTL1CYP3A4HPGDCYP2C19 | |
| SCHEMBL6565744 | 0.80 | GAA (0.46) | GAAL3MBTL1CYP3A4HPGDCYP2C19 | |
| SCHEMBL18091210 | 0.80 | GAA (0.44) | GAAL3MBTL1BCHE | |
| SCHEMBL21226993 | 0.80 | SLC6A4 (0.48) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1996538-A1 | METHOD FOR PREPARATION OF AROMATIC CHLOROFORMATES | Sabic Innovative Plastics IP B.V. (NL) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007001757-A1 | METHOD FOR PREPARATION OF AROMATIC CHLOROFORMATES | GENERAL ELECTRIC COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | GAA 298/4885L3MBTL1 744/4885CYP3A4 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.